VANESSA ARTEAGA-CHEN: Open Payments
NPI 1164787461 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,893 in 99 payments from 29 companies in 2025. Trend: 2023 $2,121 · 2024 $3,787 · 2025 $2,893
Food & beverage: $1,893Long term medical supply or device loan: $1,000
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 29 | $1,337 |
| AstraZeneca Pharmaceuticals LP | 13 | $321 |
| Merck Sharp & Dohme LLC | 9 | $177 |
| Daiichi Sankyo Inc. | 4 | $88 |
| ABBVIE INC. | 3 | $73 |
| Incyte Corporation | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $64 |
| GlaxoSmithKline, LLC. | 3 | $64 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $63 |
| Regeneron Healthcare Solutions, Inc. | 2 | $56 |
Products named: KISQALI, KEYTRUDA, Enhertu, SCEMBLIX, IMFINZI, Fabhalta, EPKINLY, LYNPARZA.
Industry payments across AZ — which companies pay providers there.
